Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13vPnC in Healthy Japanese Adults
NCT00562354Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Primary completion
- Dec 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Prevnar 13 in pneumococcal infection (2 arms), sponsored by Pfizer. Primary endpoints: Pneumococcal Opsonophagocytic Activity Geometric Mean Titers at 1 month and Pneumococcal Opsonophagocytic Activity Geometric Mean Fold Rises at 1 month. Started Oct 2007; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00562354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562354.